Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0JF9Z
|
|||
| Former ID |
DIB012324
|
|||
| Drug Name |
CSL-362
|
|||
| Synonyms |
CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [1] | |
| Company |
Csl; janssen research & development
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 3 receptor (CSF2RB) | Target Info | . | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Apoptosis | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Reactome | GPVI-mediated activation cascade | |||
| G beta:gamma signalling through PI3Kgamma | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| RAF/MAP kinase cascade | ||||
| Surfactant metabolism | ||||
| Interleukin receptor SHC signaling | ||||
| WikiPathways | IL-3 Signaling Pathway | |||
| Interleukin-2 signaling | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01632852) A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission. U.S. National Institutes of Health. | |||
| REF 2 | Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.